February 6, 2026 · Form 4 insider transaction
Glessner Coleen sold 28,847 shares of Emergent BioSolutions Inc. at $10.92 per share, a transaction worth $315.0K. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 4 days after the transaction.
Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023.